Intratect (Human Normal Immunoglobulin)

Human Normal Immunoglobulin supplies a broad range of IgG antibodies derived from healthy donors. These antibodies neutralize pathogens, modulate complement activation, and interact with immune cells to regulate cytokine release and Fc‑receptor signaling, thereby offering passive immunity and correcting antibody deficiencies.

The dosing of Intratect is individualized and determined by the prescribing clinician based on the patient’s specific condition, weight, and clinical response. Healthcare providers calculate the appropriate dose and infusion schedule, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety data for Intratect in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use is reserved for situations where the potential benefit justifies any possible risk to the fetus or infant, and decisions should be made by the treating physician.

To request Intratect, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and necessary import documentation.

Intratect contains pooled human IgG similar to other IVIG preparations, offering comparable efficacy for immune replacement and modulation. Differences may lie in manufacturing processes, stabilizers, and concentration, which can affect infusion volume, tolerability, and supply chain considerations. Clinicians choose a product based on patient response, safety profile, and availability.

Intratect must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Proper cold‑chain handling ensures product stability and maintains its therapeutic potency.

Intratect is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are determined by the prescriber, often starting slowly to monitor tolerance and then increasing as needed. Patients are observed for any adverse reactions during and after the infusion.

Serious risks include aseptic meningitis, thromboembolic events, acute renal failure, hemolytic anemia, and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of these complications, especially during the first few infusions.

Intratect is contraindicated in patients with known severe IgA deficiency who have experienced anaphylactic reactions to immunoglobulin products, and in individuals with uncontrolled hyperviscosity or active severe infections where IVIG could exacerbate the condition. Clinicians must evaluate each patient’s medical history before initiating therapy.